AIM ImmunoTech announced that stockholders approved all proposals at its Special Meeting on July 15, 2026. Key approvals include granting the Board of Directors authority to enact a reverse stock split and authorizing the potential issuance of significant shares tied to various warrants and promissory notes.
Key Details
- Reverse Stock Split: Shareholders approved a reverse stock split of the company's common stock at a ratio of up to 1-for-25, with the exact ratio and timing to be determined by the Board of Directors.
- Warrant-Related Share Issuance: The company received approval to issue over 19.99% of its outstanding common stock upon the potential exercise of Class H, I, and J warrants related to agreements from May and June 2026.
- Note Conversion Approval: Approval was also granted for the potential issuance of over 19.99% of outstanding common stock upon the conversion of two promissory notes dated February 16, 2024, and November 18, 2025.